Indivior PLC (INDV)
NASDAQ: INDV · Real-Time Price · USD
11.34
+0.26 (2.35%)
At close: May 12, 2025, 4:00 PM
11.90
+0.56 (4.94%)
After-hours: May 12, 2025, 7:58 PM EDT
Indivior Revenue
Indivior had revenue of $266.00M in the quarter ending March 31, 2025, a decrease of -6.34%. This brings the company's revenue in the last twelve months to $1.17B, up 4.09% year-over-year. In the year 2024, Indivior had annual revenue of $1.19B with 8.69% growth.
Revenue (ttm)
$1.17B
Revenue Growth
+4.09%
P/S Ratio
1.19
Revenue / Employee
$1,113,225
Employees
1,051
Market Cap
1.39B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.19B | 95.00M | 8.69% |
Dec 31, 2023 | 1.09B | 192.00M | 21.31% |
Dec 31, 2022 | 901.00M | 110.00M | 13.91% |
Dec 31, 2021 | 791.00M | 144.00M | 22.26% |
Dec 31, 2020 | 647.00M | -138.00M | -17.58% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
INDV News
- 11 days ago - New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy - PRNewsWire
- 14 days ago - Indivior: Trying To Break Addiction - Seeking Alpha
- 18 days ago - Indivior PLC (INDV) Q1 2025 Earnings Conference Call Transcript - Seeking Alpha
- 18 days ago - Indivior Announces Q1 2025 Financial Results - PRNewsWire
- 2 months ago - Indivior Announces Further Changes to Board of Directors - PRNewsWire
- 2 months ago - UK's Indivior appoints Joe Ciaffoni as CEO - Reuters
- 2 months ago - Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer - PRNewsWire
- 2 months ago - Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection - PRNewsWire